Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years.

NCT00328107 is registered in ClinicalTrials.gov with Protein Sciences Corporation as lead sponsor.

NCT NCT00328107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00328107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years.
Lead sponsor
Protein Sciences Corporation
Phase
Phase 2/3
Overall status
Completed
Start date
November 30, 2004
Completion date
August 31, 2005
Enrollment
459 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

influenza